Karolinska Development portfolio company Aprea presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine for the treatment of mutated myelodysplastic syndrome

STOCKHOLM, sweden – april 16, 2018. Karolinska Development AB (Nasdaq Stockholm: KDEV) announced today that portfolio company Aprea Therapeutics presents initial positive results at the annual meeting in 2018

The American Association of Cancer Research (AACR) in Chicago from the ongoing phase Ib/II clinical trial of APR-246 in patients with MDS. The current study evaluates the safety and efficacy of APR-246 in combination with azacytidin for the treatment of TP53-mutated MDS.

The total responsfrekvensen (ORR) of the 8 evaluable patients was 100%, including 6 patients achieved a complete response (CR) and 2 patients achieved marrow CR (mCR). Median progression-free survival and overall survival has not yet been achieved in the study, and no respondents patients have experienced relapse.

At the data cutoff had 4 CR-patients fully in response, with the result of further CR-patients in anticipation of the analysis.

Side effects (AE) during the APR-246 monotherapy-the start-up phase were all grade 1. No dosbegränsande toxiciteter has been experienced so far.

“These initial results are very encouraging and we look forward to seeing the full results of the study and the benefits for the MDS patients,” says Viktor Drvota, CEO of Karolinska Development.

For more information about the study and results, please visit www.aprea.com

For further information, please contact the

:

Viktor Drvota, CEO, Karolinska Development AB

Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

If Aprea Therapeutics

Aprea Therapeutics (Stockholm, Sweden and Boston, USA) is a biotechnology company that develops novel anticancer compounds targeting the tumörsupressorproteinet p53. Apreas leading drug candidate APR-246 has been shown to re-activate mutated p53 protein, which causes programmed cell death in many cancer cells in humans.

  

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a nordic investment company in the field of life science. The company focuses on identifying the medical innovations and to invest in order to create and develop companies that develop such innovations into differentiated products that can make a difference to patients ‘ lives, and generate an attractive return to shareholders.

Karolinska Development has access to medical research in the world from Karolinska Institutet and other leading universities and research institutions in the Nordic countries. The company’s goal is to build a company around researchers who are leaders in their respective fields of science, with support from the experienced management teams and advisors, and funding with international investors specialized in the sector.

Karolinska Development portfolio consists of nine companies focused on developing innovative treatments for diseases that are life-threatening or debilitating, and other medical conditions.

The company is managed by a entreprenörsteam consisting of investment professionals with extensive experience in company-building and with access to a strong global network.

For more information: www.karolinskadevelopment.com.

This information is such information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted by Viktor Drvota for publication on 16 april 2018 14:59.

PR Aprea April 2018 (Eng)-

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Karolinska Development AB (publ) via Globenewswire

Leave a Reply